An official website of the United States government. Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to. Myocarditis related to COVID-19 vaccines seems to be caused by the bodys immune response to vaccination. Block, J. P., Boehmer, T. K., Forrest, C. B., Carton, T. W., Lee, G. M., Ajani, U. They help us to know which pages are the most and least popular and see how visitors move around the site. Most patients with myocarditis or pericarditis who received care responded well to medicine and rest and felt better quickly. 76% were classified as mild and 22% intermediate. Myocarditis usually goes away on its own with supportive care, including IV fluids, steroid therapy, and medicines to treat disorders of heart rhythm or pumping function. Among patients in a large Israeli health care system who had received at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the . * This analysis evaluated direct benefits and harms, per million second doses of mRNA COVID-19 vaccine given in each age group, over 120 days. CDC is not responsible for the content
These are normal signs that your body is making protective antibodies. Follow-up is ongoing to identify and understand longer-term outcomes after myocarditis occurring after COVID-19 vaccination. <>/Metadata 2557 0 R/ViewerPreferences 2558 0 R>>
Among males aged 30 years, 15,300 COVID-19 cases, 4,598 hospitalizations, 1,242 ICU admissions, and 700 deaths could be prevented, compared with three to four expected myocarditis cases after COVID-19 vaccination. Within the Vaccine Adverse Event Reporting System (VAERS) (4), the national vaccine safety passive monitoring system, 1,226 reports of myocarditis after mRNA vaccination were received during December 29, 2020June 11, 2021. Unable to load your collection due to an error, Unable to load your delegates due to an error. MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services. Klamer, T. A., Linschoten, M., & Asselbergs, F. W. (2022). the rates per million doses were roughly 52 with the Pfizer shots and . All information these cookies collect is aggregated and therefore anonymous. This conversion might result in character translation or format errors in the HTML version. A histopathologic definition and classification. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87%). All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html. Thank you for taking the time to confirm your preferences. endobj
xVMo8#Yi~*vSh6vm";Bk+;#{7BWAl)q7MgGSs]Hg>^Dx+2
2Mz49K-+i2\?')I!crVZ Pv)(v0Rv0`U4')>og)o|VA( CpN4yLc7zL''E->3`Vlk2dmUH'IS[X,sKWsQh
&5ER(BBze?>M>#)V. More often after the second dose Patients can usually return to their normal daily activities after their symptoms improve. Symptoms typically include chest pain, dyspnea, or palpitations, although other symptoms might be present, especially in younger children (3). Conclusions and relevance: COVID-19 is more likely than vaccines to cause myocarditis, and symptoms and outcomes are often worse. Thank you for taking the time to confirm your preferences. %PDF-1.7
Reporting rates of myocarditis > background rates for males (12-49 years, depending upon dose and manufacturer) and females (after dose 2, 12-29 . The data that the agencies are reviewing were provided by the Canadian government. The crude reporting rates for cases of myocarditis within 7 days after COVID-19 vaccination exceeded the expected rates of myocarditis across multiple age and sex strata. <>
Serious side effects are very uncommon. Cases have mostly occurred in adolescents and young adults under the age of 30 years and mostly in males. A small number of myocarditis and pericarditis cases have been reported for booster doses. COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices United States, June 2021. They also recover normal heart function sooner.12. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. Reporting rates of adverse events following COVID-19 vaccination, including those from booster doses, are very stable. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, Secora A, McMahill-Walraven CN, Lu Y, Wu Y, Ogilvie RP, Reich C, Djibo DA, Wan Z, Seeger JD, Akhtar S, Jiao Y, Chillarige Y, Do R, Hornberger J, Obidi J, Forshee R, Shoaibi A, Anderson SA. Coronavirus-induced myocarditis: A meta-summary of cases. Age was not reported for 32 patients, and sex was not reported for 14 patients. In addition, CDC has updated patient education and communication materials reflecting this information for the Pfizer-BioNTech and Moderna****** COVID-19 vaccines; these are important to ensure that vaccine recipients, especially males aged 1229 years, are aware of increased risk for myocarditis and to seek care if they develop symptoms of myocarditis. 8600 Rockville Pike Disclaimer. Data were used for the most recent week not subject to reporting delays prior to the ACIP meeting. Among individuals older than 40 years of age, there were no more than 8 reports of myocarditis for any individual age after receiving either vaccine. To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US. mRNA Vaccine Technology: A Promising Idea for Fighting HIV, Testing of mRNA HIV vaccines in humans is underway. January 07, 2022 The risk of myocarditis after immunization with mRNA-based vaccines against SARS-CoV-2 raised concerns when it came to light in early 2021. endobj
Of the nearly 21 million women, 7.2 million (34%) were younger than age 40, and a slightly increased risk of myocarditis was found among this younger age group after receiving a second dose of the Moderna COVID-19 vaccine: 7 estimated extra cases of myocarditis for every one million women vaccinated. Among teenaged boys the group with the highest risk of myocarditis after COVID-19 vaccination the risk is between 2 and 5 times higher after SARS-CoV-2 infection than after vaccination.10, A study of children ages 12 to 17 in England estimated that COVID-19 vaccination prevented 4,500 hospitalizations, 300 ICU hospital stays, and 36 deaths during the summer of 2021 when infection rates were high.11, Children with myocarditis linked with vaccination are less likely to be hospitalized, admitted to the ICU, or need ventilator support, compared with children who had myocarditis after a COVID-19 diagnosis. Unauthorized use of these marks is strictly prohibited. Severe myocarditis can cause long-lasting heart damage or even death. Informed by early reports, CDC prioritized rapid review of myocarditis in persons aged <30 years reported during May 1June 11, 2021; the 484 patient records in this subset were evaluated by physicians at CDC, and several reports were also reviewed with Clinical Immunization Safety Assessment Project investigators, including cardiologists. Su, J. R., McNeil, M. M., Welsh, K. J., Marquez, P. L., Ng, C., Yan, M., & Cano, M. V. (2021). Among 192 405 448 persons receiving a total of 354 100 845 mRNA-based COVID-19 vaccines during the study period, there were 1991 reports of myocarditis to VAERS and 1626 of these reports met the case definition of myocarditis. National Library of Medicine The most common symptoms are chest pain, fever, fatigue, shortness of breath, and a rapid or irregular pulse. Centers for Disease Control and Prevention. Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis. Members of the Advisory Committee on Immunization Practices COVID-19 Vaccines Work Group: Edward Belongia, Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute; Dayna Bowen Matthew, George Washington University Law School; Oliver Brooks, National Medical Association; Jillian Doss-Walker, Indian Health Service; Marci Drees, Society for Healthcare Epidemiology of America; Jeffrey Duchin, Infectious Diseases Society of America; Kathy Kinlaw, Center for Ethics, Emory University; Doran Fink, Food and Drug Administration; Sandra Fryhofer, American Medical Association; Jason M. Goldman, American College of Physicians; Michael Hogue, American Pharmacists Association; Denise Jamieson, American College of Obstetricians and Gynecologists; Jeffery Kelman, Centers for Medicare & Medicaid Services; David Kim, U.S. Department of Health and Human Services; Susan Lett, Council of State and Territorial Epidemiologists; Kendra McMillan, American Nurses Association; Kathleen Neuzil, Center for Vaccine Development and Global Health, University of Maryland School of Medicine; Sean OLeary, American Academy of Pediatrics; Christine Oshansky, Biomedical Advanced Research and Development Authority; Stanley Perlman, Department of Microbiology and Immunology, University of Iowa; Marcus Plescia, Association of State and Territorial Health Officials; Chris Roberts, National Institutes of Health; William Schaffner, National Foundation for Infectious Diseases; Kenneth Schmader, American Geriatrics Society; Bryan Schumacher, Department of Defense; Rob Schechter, Association of Immunization Managers; Jonathan Temte, American Academy of Family Physicians; Peter Szilagyi, University of California, Los Angeles; Matthew Tunis, National Advisory Committee on Immunization Secretariat, Public Health Agency of Canada; Thomas Weiser, Indian Health Service; Matt Zahn, National Association of County and City Health Officials; Rachel Zhang, Food and Drug Administration. Feelings of having a fast-beating, fluttering, or pounding heart Myocarditis and pericarditis have rarely been reported. Although numbers were too small to show rates in all subgroups by age, VSD data indicated increased risk of myocarditis in the 7 days after receipt of dose 1 or dose 2 of an mRNA COVID-19 vaccine compared with the risk 2242 days after the second dose, particularly among younger males after dose 2 (5). J Med Toxicol. No other disclosures were reported. Of the 323 persons meeting CDCs case definitions, 309 (96%) were hospitalized. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C., Channon, K. M., Mills, N. L., Sheikh, A., & Hippisley-Cox, J. The clinical presentation and severity of myocarditis vary among patients. Diagnostic evaluation might reveal an elevated troponin level or abnormal findings on electrocardiogram, echocardiogram, or cardiac magnetic resonance imaging (Table 1). NHLBI Information & Resources on COVID-19. A., & American Heart Association Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young and Stroke Council (2021). Posts making claims regarding the mortality rate of children diagnosed with COVID-19-linked myocarditis are viewable here, here. The estimated incidence of myocarditis was 2 per 100,000 individuals, with the highest reported rate in males aged 16 to 29. If you have concerns about COVID-19 vaccination, talk with your healthcare provider or your childs doctor, nurse, or clinic. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). The scientists are monitoring the health of a diverse group of people to learn about the long-term effects of COVID, including heart problems. "If you're focused on heart inflammation, the safer bet is to take the vaccine," said Mendel Singer at Case Western Reserve University in Ohio, who helped carry out the study. The .gov means its official. Most people recover fully with rest and a few days of supportive treatment while being monitored in a hospital. Reporting rates (per 1 million doses administered) of myocarditis among females after Moderna COVID-19 vaccination, days 0-7 after vaccination (through Jan 13, 2022 6 Moderna (Females) Ages (years) Dose 1 Dose 2 18-24 0.5 5.5 25-29 0.3 5.8 30-39 0.6 0.6 40-49 0.8 1.6 50-64 0.8 0.4 65+ 0.1 0.5 85,729,766 Overall, the investigators found 2.13 myocarditis cases per 100,000 peopleagain, about a 0.002% incidencewith the highest incidence in men 16 to 29 years old, where it was 10.69 cases per 100,000 people, or a 0.011% incidence (95% CIs, 1.56 to 2.70 and 6.93 to 14.46, respectively). **** https://gis.cdc.gov/grasp/COVIDNet/COVID19_5.html. Clipboard, Search History, and several other advanced features are temporarily unavailable. The known risks of COVID-19 illness and its related, possibly severe complications, such as long-term health problems, hospitalization, and even death, far outweigh the potential risks of having a rare adverse reaction to vaccination, including the possible risk of myocarditis or pericarditis. Preliminary evidence on long COVID in children. All EUA documents for COVID-19 vaccines, including fact sheets, are available at https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccinesexternal icon. Association Between Myocarditis and Mortality in COVID-19 Patients in a Large Registry. Its also possible that myocarditis linked with vaccination is less serious because of the younger average age and healthier status of people getting vaccinated. Impact of COVID-19 on Cardiovascular Disease. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. Both Pfizer-BioNTech and Moderna vaccines are mRNA vaccines encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Dr Schlaudecker reported receiving grants from Pfizer and receiving personal fees from Sanofi Pasteur. From an analysis done on just 26 medical chart-confirmed cases of myocarditis in people ages 12 to 39, the CDC scientists estimated a rate of 12.6 cases per million second doses. The study shows a low but significant rate of myocarditis among vaccine recipients, at less than 1 per 100,000 recipients. doi: 10.1136/bmj-2021-069445. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. There might be a 2.5 times higher . * Persons who lack the listed symptoms but who meet other criteria may be classified as subclinical myocarditis (probable or confirmed). Using the Dallas criteria (Aretz HT, Billingham ME, Edwards WD, et al. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Vaccine 2015;33:4398405. Per million second doses of mRNA COVID-19 vaccine administered to males aged 1229 years, 11,000 COVID-19 cases, 560 hospitalizations, 138 ICU admissions, and six deaths due to COVID-19 could be prevented, compared with 3947 expected myocarditis cases after COVID-19 vaccination (Table 2). Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected. Since June 2020, ACIP has convened 15 public meetings to review data on COVID-19 epidemiology and use of COVID-19 vaccines. US researchers say teenagers are more likely to get vaccine-related myocarditis than end up in hospital with Covid Skip to main content Skip to navigation Print subscriptions Even in this group, though, heart inflammation is seven or eight times more common after SARS-CoV-2 infection.10 And the data suggest that young adults with myocarditis possibly linked with COVID-19 vaccines recover quickly with supportive care.11. Buonsenso D, Munblit D, De Rose C, et al. CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. We dont know exactly how often this happens, but one study estimated that myocarditis affects about 40 people out of every 1,000,000 people who test positive for COVID-19.3 However, myocarditis is much more common in patients hospitalized for COVID-19 (226 per 100,000). 2023 Feb 1;6(2):e2253845. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/risk-benefit-analysis.html. The https:// ensures that you are connecting to the Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L. BMJ. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are 12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age. Viruses. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT Jr. JAMA Cardiol. Regarding health equity considerations, racial and ethnic minority groups have higher rates of COVID-19 and severe disease*****; potential changes in vaccine policy, or anything that would affect vaccination coverage for adolescents or young adults, might disproportionately affect those groups with the highest rates of poor COVID-19 outcomes. The Pfizer and Moderna mRNA vaccines are available in the U.S. JAMA Netw Open. 2023 Feb 5;11(2):362. doi: 10.3390/vaccines11020362. The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr)
Views equals page views plus PDF downloads. Health and Human Services. Julia W. Gargano, PhD1,*; Megan Wallace, DrPH1,*; Stephen C. Hadler, MD1; Gayle Langley, MD1; John R. Su, MD, PhD1; Matthew E. Oster, MD1; Karen R. Broder, MD1; Julianne Gee, MPH1; Eric Weintraub, MPH1; Tom Shimabukuro, MD1; Heather M. Scobie, PhD1; Danielle Moulia, MPH1; Lauri E. Markowitz, MD1; Melinda Wharton, MD1; Veronica V. McNally, JD2; Jos R. Romero, MD3; H. Keipp Talbot, MD4; Grace M. Lee, MD5; Matthew F. Daley, MD6; Sara E. Oliver, MD1 (View author affiliations). Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. CDC continues to recommend that everyone ages 6 months and older get vaccinated for COVID-19. Myocarditis was reported at a higher rate than expected among some people who received the Pfizer or Moderna vaccines, according to a July 2021 study. According to an analysis presented by a C.D.C. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. People who experience a serious side effect of a vaccine or other medical products for COVID-19 may be eligible for compensation under the federal Countermeasures Injury Compensation Program. Among men ages 18 to 29 who received the Moderna vaccine, the rate was 22.9 per 100,000 doses. The NHLBI supports and conducts research aimed at understanding risk factors for COVID-19, developing prevention and treatment strategies, and finding ways to hasten and enhance recovery. The review said they were all either elderly or had other health conditions. The benefit-risk analysis can be updated as needed to reflect changes in the COVID-19 pandemic and additional information on the risk for and outcomes of myocarditis after COVID-19 vaccination. (2022). A recent study classifying Long COVID into four types can help health care providers better target treatments for a patients specific symptoms. Myocarditis reporting rates were 40.6 cases per million second doses of mRNA COVID-19 vaccines administered to males aged 1229 years and 2.4 per million second doses administered to males aged 30 years; reporting rates among females in these age groups were 4.2 and 1.0 per million second doses, respectively. A, For the BNT162b2 vaccine, there were 138 reported cases of myocarditis with known date for symptom onset and dose after 114246837 first vaccination doses and 888 reported cases after 95532396 second vaccination doses. Objective: Its important to remember that any vaccine can cause side effects. mmwrq@cdc.gov. This is a recognised risk with the Comirnaty (Pfizer) and Spikevax (Moderna) vaccines and we are closely monitoring these events. Higher levels of vaccination coverage can reduce community transmission, which can protect against development and circulation of emerging variants. The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). (Jolygon/iStock via Getty Images) The risk of developing myocarditis - an inflammation of the heart muscle - following a booster dose of the Pfizer COVID-19 vaccine is low, according to new research from Israel. Myocarditis typically occurs more commonly in males than in females, and incidence is highest among infants, adolescents, and young adults (1,2). Data sources: Klamer et al., 2022; Cordero et al., 2022; National Weather Service. Evidence suggests that AstraZeneca and Novavax are probably associated with a small increased risk of myocarditis and pericarditis. Myocarditis rates from Vaccine Safety Datalink (VSD), based on electronic health records, were also evaluated. The CONNECTS-Collaborative Cohort of Cohorts for COVID-19 Research (CONNECTS-C4R) trial is enrolling 50,000 people to determine factors that may predict disease severity and long-term side effects of COVID-19. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. Mary Chamberland, Thomas Clark, Amanda Cohn, Frank DeStefano, Ruth Gallego, Alice Guh, Theresa Harrington, Fiona P. Havers, Lauri Hicks, Amelia Jazwa, Tara Johnson, Brian Kit, Paige Marquez, Sarah Mbaeyi, Elaine Miller, Hannah Rosenblum, Monica Parise, Kadam Patel, Pragati Prasad, David Shay, Jamila Shields, Christopher A. Taylor, Joshua Wong, CDC COVID-19 Response Team; Clinical Immunization Safety Assessment (CISA) Project; Vaccine Safety Datalink; Center for Biologics Evaluation and Research, Food and Drug Administration; Voting members of the Advisory Committee on Immunization Practices: Kevin A. Ault, University of Kansas Medical Center; Lynn Bahta, Minnesota Department of Health; Henry Bernstein, Zucker School of Medicine at Hofstra/Northwell Cohen Childrens Medical Center; Beth Bell, University of Washington, Seattle, Washington; Wilbur Chen, University of Maryland School of Medicine; Sharon E. Frey, Saint Louis University Medical School; Camille Kotton, Harvard Medical School; Sarah Long, Drexel University College of Medicine; Katherine A. Poehling, Wake Forest School of Medicine; Pablo J. Snchez, The Research Institute at Nationwide Childrens Hospital. Key factors to consider are the current rates of COVID-19 infection, the childs overall health, and the parents assessment of risks. Myocarditis linked with COVID-19 illness may also be more severe because these patients are usually older and have other health conditions that increase their risk of complications. Cordero, A., Cazorla, D., Escribano, D., Quintanilla, M. A., Lpez-Ayala, J. M., Berbel, P. P., & Bertomeu-Gonzlez, V. (2022). The CDC also needs to recommend . Centers for Disease Control and Prevention. For children ages 6 months to 2 years, efficacy was 43.7 percent, and in children ages 2 to 6, it was only 37.5 percent. See this image and copyright information in PMC. These cookies may also be used for advertising purposes by these third parties. stream
In a population-based cohort study of adolescents and adults in Denmark who received two doses of the same mRNA vaccine against COVID, the risk of myocarditis or myopericarditis within 28 days. Lancet. They help us to know which pages are the most and least popular and see how visitors move around the site. Some people may have minimal or no symptoms. FLEG: Vaccination helps protect people from getting sick or severely ill with COVID-19 and helps protect those around them. Payne AB, Gilani Z, Godfred-Cato S, et al. There were likely many cases that went unreported. 2022 May 24;327(20):2019-2020. doi: 10.1001/jama.2022.5131. *** The highest reporting rates were among males aged 1217 years and those aged 1824 years (62.8 and 50.5 reported myocarditis cases per million second doses of mRNA COVID-19 vaccine administered, respectively). Hromi-Jahjefendi A, Barh D, Uversky V, Aljabali AA, Tambuwala MM, Alzahrani KJ, Alzahrani FM, Alshammeri S, Lundstrom K. Vaccines (Basel). Department of Health and Human Services. official website and that any information you provide is encrypted provided as a service to MMWR readers and do not constitute or imply
HHS Vulnerability Disclosure, Help endobj
ACIP emphasized the importance of informing vaccination providers and the public about the benefits and the risks, including the risk for myocarditis after COVID-19 vaccination, particularly for males aged 1229 years. This site needs JavaScript to work properly. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology. Crude reporting rates were calculated across age and sex strata. The numbers of events per million persons aged 1229 years are the averages of numbers per million persons aged 1217 years, 1824 years, and 2529 years. Receipt of 2 doses of mRNA COVID-19 vaccine, compared with no vaccination. Case numbers have been rounded to the nearest hundred. Ranges calculated as 10% of crude VAERS reporting rates. Abbreviations: AV = atrioventricular; cMRI=cardiac magnetic resonance imaging; ECG or EKG=electrocardiogram. This risk should be considered in the context of the benefits of COVID-19 vaccination. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. Questions or messages regarding errors in formatting should be addressed to
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data. . Males comprised 82% of the myocarditis cases for whom sex was reported. government site. I doubt we'll ever know. MMWR Morb Mortal Wkly Rep 2021;70:977982.